Worm D, Handberg A, Hoppe E, Vinten J, Beck-Nielsen H
Diabetes Research Centre, Odense University Hospital, Denmark.
Diabetologia. 1996 Feb;39(2):142-8. doi: 10.1007/BF00403956.
In order to measure the phosphotyrosine phosphatase (PTPase) activity in small muscle biopsies, a sandwich-immunofluorescence assay was developed using the phosphorylated human insulin receptor as a substrate, a C-terminal insulin receptor antibody as catching antibody and Europium-labelled anti-phosphotyrosine as detecting antibody. Soluble and particulate muscle fractions were prepared from soleus muscle of obese, diabetic (fa/fa) Zucker rats and their lean littermates (Fa/-). In the soluble muscle fractions of the obese (fa/fa) rats PTPase activity was significantly reduced compared to control (Fa/-) rats (45.2 +/- 2.6% vs 61.3 +/- 4.7%, p < 0.02). This reduction was completely prevented by 24 days of metformin treatment which decreased plasma glucose and plasma insulin levels. In particulate muscle fractions, however, no difference in PTPase activity was found among any groups of rats examined. These results show that the alterations in soluble PTPase activity in the insulin-resistant, diabetic Zucker rat vary with the abnormality in glucose homeostasis.
为了测量小块肌肉活检组织中的磷酸酪氨酸磷酸酶(PTPase)活性,我们开发了一种夹心免疫荧光测定法,该方法使用磷酸化的人胰岛素受体作为底物,C端胰岛素受体抗体作为捕获抗体,铕标记的抗磷酸酪氨酸作为检测抗体。从肥胖、糖尿病(fa/fa) Zucker大鼠及其瘦同胞(Fa/-)的比目鱼肌中制备可溶性和颗粒性肌肉组分。与对照(Fa/-)大鼠相比,肥胖(fa/fa)大鼠的可溶性肌肉组分中的PTPase活性显著降低(45.2±2.6%对61.3±4.7%,p<0.02)。二甲双胍治疗24天可降低血糖和血浆胰岛素水平,完全阻止了这种降低。然而,在颗粒性肌肉组分中,在所检查的任何大鼠组中均未发现PTPase活性存在差异。这些结果表明,胰岛素抵抗的糖尿病Zucker大鼠中可溶性PTPase活性的改变随葡萄糖稳态异常而变化。